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Small-Molecule Proteomimetic Inhibitors of the
HIF-1a–p300 Protein–Protein Interaction
George M. Burslem,[a, b] Hannah F. Kyle,[b, c] Alexander L. Breeze,[d] Thomas A. Edwards,[b, c]
Adam Nelson,[a, b] Stuart L. Warriner,[a, b] and Andrew J. Wilson*[a, b]
The therapeutically relevant hypoxia inducible factor HIF-1a–
p300 protein–protein interaction can be orthosterically inhibit-
ed with a-helix mimetics based on an oligoamide scaffold that
recapitulates essential features of the C-terminal helix of the
HIF-1a C-TAD (C-terminal transactivation domain). Preliminary
SAR studies demonstrated the important role of side-chain size
and hydrophobicity/hydrophilicity in determining potency.
These small molecules represent the first biophysically charac-
terised HIF-1a–p300 PPI inhibitors and the first examples of
small-molecule aromatic oligoamide helix mimetics to be
shown to have a selective binding profile. Although the com-
pounds were less potent than HIF-1a, the result is still remark-
able in that the mimetic reproduces only three residues from
the 42-residue HIF-1a C-TAD from which it is derived.
An emerging goal in cancer chemotherapy is to target meta-
bolic and cellular processes that enable the survival and
growth of tumours.[1] The transcription factor, hypoxia induci-
ble factor (HIF), plays a central role in the cellular response to
hypoxia. HIF exists as three isoforms (1–3), with HIF-1 and, to
a lesser extent, HIF-2 identified as drivers of tumour growth.[2]
HIF-1 is a heterodimer made up of two subunits : HIF-1a and
HIF-1b (HIF-1b is also referred to as aryl hydrocarbon receptor
nuclear translocator, ARNT). Under normoxic conditions HIF-1a
is rapidly degraded through an oxygen-dependent process
with the von Hippel–Lindau protein (pVHL) playing a dominant
role.[3] Under hypoxic conditions, however, the protein HIF-1a
is stabilised and translocated to the nucleus, where it forms
heterodimers and recruits transcriptional coactivator proteins
such as p300,[4, 5] and this leads to the hypoxic response cas-
cade. This results in expression of multiple genes (e.g. , VEGF)
that participate in angiogenesis, various metabolic processes
and cell proliferation and survival. Solid tumours develop rap-
idly, and oxygen supply diminishes; cancerous cells thus ex-
ploit the hypoxic response pathway to initiate resupply of the
tumour with oxygen through formation of new vasculature.
Targeting the HIF pathway has therefore become the focus
of efforts to develop small-molecule inhibitors.[2] However,
HIF’s function as a transcription factor is exerted through pro-
tein–protein interactions (PPIs). PPIs are considered challenging
targets for small-molecule ligands, given that the target surfa-
ces for competitive inhibition are typically large and less well
defined than conventional small-molecule binding “pock-
ets”.[6, 7] Despite this, several approaches to target the HIF path-
way have been described. Inhibitors of the VHL–HIF-1a inter-
action (identified through fragment approaches),[8] polyamide
inhibitors of HIF-1–DNA binding,[9] cyclic peptide inhibitors of
HIF-1 heterodimerization (identified through screening of ge-
netically encoded cyclic peptide libraries),[10] orthosteric inhibi-
tors of HIF-1b–coactivator interactions[11] and allosteric small
molecules that attenuate HIF-2 dimerization[12] have all been
described.
Inhibition of the HIF-1a–p300 interaction[13] also represents
an attractive approach for modulation of HIF-1a ; identification
of selective and specific probe molecules should facilitate stud-
ies of the HIF pathway and might be advantageous in terms of
developing therapies. Natural products, such as chetomin (1,
Figure 1A),[14] and other epidithioketopiperazine (ETP)-contain-
ing small molecules[15] have been reported to act as HIF-1a–
p300 inhibitors; however, the ETP motif ejects structurally im-
portant zinc from p300, and so these compounds are unlikely
to act as selective and specific inhibitors.[16] Similarly, small mol-
ecules[17–19] such as compound 2 (Figure 1A),[18,19] obtained by
high-throughput screening in cellular assays, have been shown
to down-regulate expression of HIF-dependent genes. Howev-
er, it is unclear whether these molecules disrupt the HIF-1a–
p300 interaction directly or prevent downstream expression in
another way, such as preventing HIF-1a expression or HIF-1a–
HIF-1b dimerization or by inhibiting necessary post-translation-
al modifications.
A published NMR structure (PDB ID: 1L8C) of the HIF-1a–
p300 complex[5] (Figure 1B) has shown that the HIF-1a C-termi-
nal transactivation domain (C-TAD) adopts an a-helical confor-
mation and wraps itself around the CH1 domain of p300 with
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the reported key residues on helices 2 and 3[20] displayed on
one face, making them an obvious target for inhibition with
designed ligands[21] such as constrained peptides,[22,23] b-pep-
tides[24] or helix mimetics.[25] Indeed, Arora and co-workers have
described hydrogen-bond-surrogate stabilized helices[26,27] that
bind to p300 as evidenced by a variety of biophysical meth-
ods,[26,27] down-regulate HIF-1a-inducible genes[26,27] and sup-
press tumour growth in murine xenograft models of renal cell
carcinoma.[26] Here we describe the first biophysically charac-
terised small-molecule inhibitors of the HIF-1a–p300 interac-
tion. We have employed a proteomimetic approach in which
an aromatic oligoamide[28] was used to project side chains
deemed essential to the PPI in a spatial orientation identical to
that in the native helix.[29–34]
Using the NMR structure (PDB ID: 1L8C) of the HIF-1a–p300
complex,[4] we designed and synthesised compounds intended
to mimic the key functionalities and spatial orientation of the
C-terminal helix (helix 3) of HIF-1a. Helix 3 presents hydropho-
bic residues along one face of the helix at the i, i+4 and i+7
positions (Figure 1B). We initially prepared the two com-
pounds 3 and 4 (Scheme 1, see the Supporting Information for
synthesis and characterisation), designed to act as direct
mimics of this helix, by the modular oligobenzamide synthetic
methodology we have previously reported.[28,29] The 3-O-alky-
lated oligobenzamide scaffold was chosen due to the robust
modular solution[28,35] and solid-supported[36] syntheses we
have developed, the ability to adopt the desired conformation
in solution[28,35] and its proven ability to inhibit a-helix-mediat-
ed PPIs.[29,30, 32] Compounds 3 and 4 (Scheme 1) recapitulate the
Leu, Leu and Val side chains in both the matched and the mis-
matched N-to-C orientation with respect to the natural helix; it
is noteworthy that prior molecular dynamics simulations sug-
gested that both parallel and antiparallel orientations can
adopt stable bound conformations with target proteins.[37]
The compounds 3 and 4 were tested in a fluorescence ani-
sotropy competition assay with a 42-residue peptide derived
from the C-TAD of HIF-1a, N-terminally labelled with FITC
through an aminohexanoic acid linker, together with residues
330–420 of the CH1 domain of p300 (see the Supporting Infor-
mation for details of assay development, protein cloning, ex-
pression and purification).[38] Upon titration of the compounds,
we observed decreases in anisotropy associated with the dis-
ruption of the interaction in a similar manner to the decrease
observed upon titration of the unlabelled peptide (Figure 2A).
In our assay the IC50 value of the unlabelled peptide is 0.23 mm,
whereas compounds 3 and 4 give IC50 values of 9.19 and
24.0 mm, respectively. The result is significant given that the 16-
residue sequence of helix 3, the basis upon which compounds
3 and 4 were designed, was shown to be inactive in the fluo-
rescence anisotropy assay (see the Supporting Information).
We attempted to perform direct binding experiments by ex-
ploiting the tryptophan fluorescence present in p300; however,
these were unsuccessful due to inner filter effects resulting
from the intrinsic fluorescence of compound 3 (see the Sup-
porting Information). Encouraged by these preliminary results,
we prepared a small library of compounds with alternative
side chains to probe the relative importance of the side chain
size and polarity. The compounds and their IC50 values are
summarised in Table 1.
Overall, the most potent compound identified was the exact
mimic of the helix side chains with the same N-to-C sequence
of side chains as the native peptide sequence. The next most
potent compound, 6, had matched top and bottom residues
but a very small difference (iBu to iPr) in the central position.
Incorporation of larger aromatic side chains (e.g. , 8), in all posi-
tions had a detrimental impact upon inhibitory potency. Addi-
Figure 1. A) Structures of previously reported inhibitors: natural product
chetomin (1)[13] and synthetic compound 2 reported by Van Meir.[14] B) NMR
structure (PDB ID: 1L8C)[5] of p300 in complex with the C-terminal transacti-
vation domain of HIF-1a (top) and excised C-terminal helix of HIF-1a show-
ing key side chains (bottom). C) X-ray crystal structure (PDB ID: 2W97)[15] of
the eIF4E–eIF4G complex (top) and the excised helix of eIF4G showing key
side chains (bottom).
Scheme 1. Structures of aromatic oligoamides.
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tionally, our structure–activity relationship studies suggest that
the R1 side chain makes important contacts within the binding
cleft through solvophobic effects. This is backed up by the re-
duced binding of 5 (because a methyl group was shown to be
insufficient to promote inhibition of the interaction) and 12
(because the introduction of polar functionality into a hydro-
phobic binding site is disfavoured). It should also be noted
that the nitroester precursor to 3 had an IC50 greater than
1 mm ; this suggests that the amine, the acid or both impart
significant affinity along with an improvement in solubility.
To gain further insight into the nature of molecular recogni-
tion, docking simulations were performed (Figure 3). These
docking studies identified a binding pose that would be ex-
pected on the basis of the pharmacophore upon which the
helix mimetics were based. Each of the three hydrophobic side
chains on 3 is matched to the position it mimics in the helix 3
sequence of the HIF-1a C-TAD. Notably, the central R2 isobutyl
side chain sits in a hydrophobic pocket defined by His20,
Leu17 and Leu16 of p300.
Considering the range of peptidomimetic compounds re-
ported in the literature, we sought to compare the activities of
the O-alkylated compounds with the activities of compounds
derived from an alternative scaffold. Oligobenzamide scaffolds
featuring alkylation on the amide nitrogen have previously
been shown to be capable of mimicking an a-helix.[31,39]
Hence, compound 13 was tested in the fluorescence anisotro-
py competition assay as a comparison with compound 6,
which features the same side chains. No inhibition of the HIF-
Figure 2. Fluorescence anisotropy competition assays for helix mimetics
tested against different helix-mediated PPIs. A) FITC-HIF-1a fluorescence ani-
sotropy competition assay data for the unlabelled HIF-1a (&), compound 3
(^) and compound 4 (~; 40 mm sodium phosphate buffer pH 7.5, 80 nm
FITC-HIF-1a, 100 nm p300). B) FITC-eIF4G fluorescence anisotropy compe-
tition assay data for compound 3 (diamonds; 40 mm sodium phosphate
buffer pH 7.5, 80 nm FITC-eIF4G, 3 mm eIF4E). Error bars represent standard
deviations of the means (n=3).
Table 1. Structures and IC50 values for compound library.
Compound R1 R2 R3 IC50 [mm]
helix 3 peptide Ac-GTEELLRALDQVNAAG-NH2 inactive
[c]
3 iBu iBu iPr 9.20.9
4 iPr iBu iBu 241.6
5 Me iPr iBu 21616[a]
6 iBu iBu iBu 9.81.3
7 iBu iPr iBu 131.5
8 benzyl benzyl benzyl 566.0
9 iPr iPr iPr 394.0
10 iBu iPr iPr 170.7
11 benzyl iPr iPr 200.8
12 2-hydroxyethyl iPr iPr 41664[a]
13[b] iPr iPr iPr inactive[c]
[a] Estimated IC50. [b] N-alkylated scaffold. [c] Up to >250 mm.
Figure 3. Molecular docking studies on compound 3 ; proposed binding
mode of compound 3 in the HIF-1a C-TAD helix 3 binding cleft with the
native peptide in transparent red. Inset: structure of HIF-1a–p300 complex
(PDB ID: 1L8C).
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 2014, 15, 1083 – 1087 1085
CHEMBIOCHEM
COMMUNICATIONS www.chembiochem.org
1a–p300 PPI was observed with 13 up to a concentration of
250 mm. This suggests that the position of functionality within
the scaffold and/or its conformation is crucial for the activities
of the inhibitors reported here.
Having developed oligoamide inhibitors, we also sought to
compare our compounds with those reported in the literature.
A modified synthesis of compound 2 was thus developed (see
the Supporting Information), and 2 was tested in our fluores-
cence anisotropy assay. Although 2 had been shown by others
to have an IC50 of 0.65 mm in a cellular reporter assay,
[19] its sol-
ubility only permitted testing in our assay up to a maximum
concentration of 25 mm ; at these concentrations we observed
no inhibition of the HIF-1a–p300 interaction; this suggests
that this compound might modulate the HIF pathway through
a different target or targets.
Finally, to ascertain whether the oligobenzamide compound
has a selective binding profile, compound 3 was tested for
inhibitory activity on another therapeutically relevant a-helix-
mediated PPI—eukaryotic initiation factor 4E/4G (eIF4E/eIF4G;
Figure 1C).[40–42] In a fluorescence anisotropy competition titra-
tion (Figure 2B; see the Supporting Information for details of
the protein, peptide preparation and assay development), the
oligobenzamide compound 3 was a weak inhibitor of this al-
ternative a-helix-mediated PPI, with an IC50>1 mm, represent-
ing over 100-fold selectivity in favour of the HIF-1a–p300 inter-
action over the eIF4E/eIF4G interaction.
In summary, we have shown that the therapeutically rele-
vant HIF-1a–p300 PPI can be orthosterically inhibited with a-
helix mimetics based on an oligoamide scaffold that recapitu-
lates essential features of the C-terminal helix of the HIF-1a C-
TAD. These compounds were shown to act as selective inhibi-
tors of this interaction, whereas preliminary SAR studies dem-
onstrated the important role of side chain size and hydropho-
bicity/hydrophilicity in determining potency. Furthermore,
these small molecules represent the first biophysically charac-
terised HIF-1a–p300 PPI inhibitors and the first examples of ar-
omatic oligoamide helix mimetics to be shown to have a selec-
tive binding profile. Although the compounds were shown to
be two orders of magnitude less potent than HIF-1a, the result
is still remarkable in that the mimetic reproduces only three
residues from the 42-residue HIF-1a C-TAD from which it is de-
rived. Crucially, the polypeptide reproducing only the 16-resi-
due C-terminal helix 3 of HIF-1a C-TAD upon which the com-
pound 3 was designed was shown to be inactive in this assay.
Our on-going studies are focused upon further elucidating the
binding mode of these compounds by other biophysical, bio-
chemical and structural techniques and upon identifying inhib-
itors active in cells.
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